Massachusetts Discontinues Coverage of GLP-1 Medications for Weight Loss

The board overseeing health insurance for Massachusetts state employees has decided to discontinue coverage of GLP-1 medications for weight loss, citing escalating healthcare costs impacting the state budget. Dana Sullivan, a board member of the Group Insurance Commission (GIC), highlighted the strategic complexity behind this decision. This move underscores the rising financial pressures due to healthcare expenditures.

The cost and usage of GLP-1 drugs, including Zepbound and Mounjaro, have substantially increased state healthcare spending. Approximately 22,000 GIC members rely on these medications for weight loss. Budget constraints and reduced federal aid have necessitated challenging fiscal decisions. Over the last two years, GIC premiums rose by 10%, prompting Governor Maura Healey to task the GIC with finding $100 million in savings. She noted GLP-1 drugs contributed to a third of the nearly 12% premium hike last year and proposed ending MassHealth’s coverage of these medications for weight management.

The GIC's decision, passed with a 10-7 vote, will take effect in the insurance year commencing in July. Sullivan indicated this measure is part of a broader approach to enhance negotiating leverage with pharmaceutical companies. Several Massachusetts insurance providers have similarly ceased covering these drugs for weight loss, anticipating potential price reductions.

Commissioner Melissa Murphy-Rodrigues voiced her opposition, expressing concern over the permanency of the measure and its implications for future budget adjustments. She questioned which other critical medications might face exclusion in similar circumstances.

Notably, GIC provides health insurance for about 460,000 individuals, including state and municipal employees, retirees, and their families. This decision solely affects those using GLP-1 drugs for weight loss, excluding treatments for conditions like diabetes.

Despite this change, GIC members’ insurance premiums are still expected to increase but less so than if GLP-1 drug coverage had continued. Previously considered measures, such as escalating copays and deductibles, faced union resistance, advocating for alternative budget solutions rather than increasing costs for public workers.

Governor Healey has urged the commission to maintain affordability by limiting changes, endorsing only the removal of weight-loss GLP-1 coverage. Union representatives, including the Massachusetts Teachers Association, have opposed the cessation, with Julianna Keyes from the Arlington Education Association criticizing the decision as "shortsighted" and highlighting the long-term benefits of medically addressing obesity.